// App-Quantinova.ai

TPS11591 : Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.

Researchers

Presenter

  • Erlinda Maria Gordon

Principal Investigators

  • Victoria S. Chua-Alcala

  • Katherine Kim

  • Shiva Sreenath Andrali

  • Marie Del Rosario

  • William W. Tseng

  • Seth Pollack

  • Sant P. Chawla

Medical Centers

  • Director, Sarcoma Oncology Center, Santa Monica, CA

  • Sarcoma Oncology Research Center, Santa Monica, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Trabectedin

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

  • Cohort

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved